704 related articles for article (PubMed ID: 26626490)
21. Bevacizumab in recurrent high-grade pediatric gliomas.
Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
[TBL] [Abstract][Full Text] [Related]
22. Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas.
Carceller F; Jerome NP; Fowkes LA; Khabra K; Mackinnon A; Bautista F; Marshall LV; Vaidya S; Mandeville H; Morgan V; Leach MO; Koh DM
Pediatr Hematol Oncol; 2019 Mar; 36(2):103-112. PubMed ID: 30978130
[No Abstract] [Full Text] [Related]
23. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
[TBL] [Abstract][Full Text] [Related]
24. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Porkholm M; Valanne L; Lönnqvist T; Holm S; Lannering B; Riikonen P; Wojcik D; Sehested A; Clausen N; Harila-Saari A; Schomerus E; Thorarinsdottir HK; Lähteenmäki P; Arola M; Thomassen H; Saarinen-Pihkala UM; Kivivuori SM
Pediatr Blood Cancer; 2014 Sep; 61(9):1603-9. PubMed ID: 24692119
[TBL] [Abstract][Full Text] [Related]
25. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas.
Wagner S; Benesch M; Berthold F; Gnekow AK; Rutkowski S; Sträter R; Warmuth-Metz M; Kortmann RD; Pietsch T; Wolff JE
Br J Cancer; 2006 Oct; 95(8):991-7. PubMed ID: 17047647
[TBL] [Abstract][Full Text] [Related]
26. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
28. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).
Benesch M; Wagner S; Berthold F; Wolff JE
J Neurooncol; 2005 Apr; 72(2):179-83. PubMed ID: 15925999
[TBL] [Abstract][Full Text] [Related]
29. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
[TBL] [Abstract][Full Text] [Related]
31. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group.
Janssens GO; Gandola L; Bolle S; Mandeville H; Ramos-Albiac M; van Beek K; Benghiat H; Hoeben B; Morales La Madrid A; Kortmann RD; Hargrave D; Menten J; Pecori E; Biassoni V; von Bueren AO; van Vuurden DG; Massimino M; Sturm D; Peters M; Kramm CM
Eur J Cancer; 2017 Mar; 73():38-47. PubMed ID: 28161497
[TBL] [Abstract][Full Text] [Related]
32. A twenty-year review of diagnosing and treating children with diffuse intrinsic pontine glioma in The Netherlands.
Veldhuijzen van Zanten SE; Jansen MH; Sanchez Aliaga E; van Vuurden DG; Vandertop WP; Kaspers GJ
Expert Rev Anticancer Ther; 2015 Feb; 15(2):157-64. PubMed ID: 25435089
[TBL] [Abstract][Full Text] [Related]
33. Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?
Lobon-Iglesias MJ; Giraud G; Castel D; Philippe C; Debily MA; Briandet C; Fouyssac F; de Carli E; Dufour C; Valteau-Couanet D; Sainte-Rose C; Blauwblomme T; Beccaria K; Zerah M; Puget S; Calmon R; Boddaert N; Bolle S; Varlet P; Grill J
J Neurooncol; 2018 Mar; 137(1):111-118. PubMed ID: 29198053
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
El-Khouly FE; Veldhuijzen van Zanten SEM; Jansen MHA; Bakker DP; Sanchez Aliaga E; Hendrikse NH; Vandertop WP; van Vuurden DG; Kaspers GJL
J Neurooncol; 2021 Jun; 153(2):263-271. PubMed ID: 33963476
[TBL] [Abstract][Full Text] [Related]
35. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study.
Fleischhack G; Massimino M; Warmuth-Metz M; Khuhlaeva E; Janssen G; Graf N; Rutkowski S; Beilken A; Schmid I; Biassoni V; Gorelishev SK; Kramm C; Reinhard H; Schlegel PG; Kortmann RD; Reuter D; Bach F; Iznaga-Escobar NE; Bode U
J Neurooncol; 2019 May; 143(1):107-113. PubMed ID: 30830679
[TBL] [Abstract][Full Text] [Related]
36. Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas.
Klimo P; Nesvick CL; Broniscer A; Orr BA; Choudhri AF
J Neurosurg Pediatr; 2016 Jan; 17(1):57-65. PubMed ID: 26474099
[TBL] [Abstract][Full Text] [Related]
37. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.
Sirachainan N; Pakakasama S; Visudithbhan A; Chiamchanya S; Tuntiyatorn L; Dhanachai M; Laothamatas J; Hongeng S
Neuro Oncol; 2008 Aug; 10(4):577-82. PubMed ID: 18559468
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
39. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
40. [Safety and efficacy of three-dimensional conformal radiotherapy combined with temozolomide in treatment of diffuse brainstem gliomas].
Fang HH; Nie Q; Kang JB; Li FM; Cai CL
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):707-9. PubMed ID: 22340055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
